Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.48 USD
Change Today +0.0501 / 11.65%
Volume 182.6K
RGRX On Other Exchanges
As of 5:20 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

regenerx biopharmaceuticals (RGRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/4/15 - $0.60
52 Week Low
08/28/14 - $0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

regenerx biopharmaceuticals (RGRX) Related Businessweek News

No Related Businessweek News Found

regenerx biopharmaceuticals (RGRX) Details

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of molecules for tissue and organ repair. The company develops and markets its product candidates based on Thymosin beta 4 (Tß4), an amino acid peptide. It develops RGN-259, a topical eye drops that that has completed the Phase IIa exploratory clinical trials and for the regeneration of corneal tissues damaged by injury, disease, or other pathology; and RGN-352, an injectable formulation, which has completed Phase I clinical trials and is intended to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications treated by systemic administration. The company also develops RGN-137, a topical gel that is in Phase II clinical trials and intended for the treatment of epidermolysis bullosa, pressure ulcers, and venous stasis ulcers. In addition, it seeks to identify and evaluate Tß4 peptide fragments and derivatives for use as components in cosmeceutical and consumer products. The company has a strategic partnership with Defiante Farmaceutica S.A. for the development and marketing of RGN-137 and RGN-352 for specified indications in Europe and other countries. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

2 Employees
Last Reported Date: 03/31/15
Founded in 1982

regenerx biopharmaceuticals (RGRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $110.8K
Compensation as of Fiscal Year 2014.

regenerx biopharmaceuticals (RGRX) Key Developments

Regenerx Biopharmaceuticals Inc. Announces Complete Data from Regenerx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology

RegeneRx Biopharmaceuticals Inc. announced a peer-reviewed publication of the results of the Company's 72-patient, placebo-controlled Phase II study evaluating RGN-259 (RegeneRx's preservative-free eye drops) for the treatment of dry eye patients using Ora Inc.'s controlled adverse environment (CAE®) model. The exploratory study was completed in late 2011, and the results, which were previously disseminated by the Company in a release, identify the key efficacy targets for a larger, multi-center, Phase IIb/III U.S. clinical trial targeted for later this year. The trial will be sponsored by ReGenTree, LLC, a U.S. joint venture owned by RegeneRx and G-treeBNT. In this just published study, a number of important outcome measures, including central, superior, and peripheral corneal staining demonstrated statistically significant improvements in the RGN-259-treated group compared to placebo (p=0.0075, p=0.0210 and p=0.0379, respectively). RGN-259 also reduced exacerbation of ocular discomfort after CAE challenge (p=0.0224). The drug candidate was well-tolerated and there were no observed adverse side effects. As reported, the co-primary outcome measures, inferior corneal staining and patient ocular discomfort 24 hours after CAE challenge, did not show statistically significant differences.

Regenerx Biopharmaceuticals Inc. Presents at SeeThruEquity 4th Annual MicroCap Investor Conference, May-28-2015 11:00 AM

Regenerx Biopharmaceuticals Inc. Presents at SeeThruEquity 4th Annual MicroCap Investor Conference, May-28-2015 11:00 AM. Venue: Convene Grand Central, 101 Park Ave, New York, NY 10178, United States. Speakers: J. J. Finkelstein, Chief Executive Officer, President and Director.

RegeneRx Biopharmaceuticals, Inc. Announces Positive Effects of Thymosin Beta 4 (TB4) in Patients with Severe Dry Eye

RegeneRx Biopharmaceuticals Inc. announced that a new medical paper has been published describing the positive effects of Thymosin beta 4 (TB4) in patients with severe dry eye. The results met key efficacy objectives of the study and the physicians stated that statistically significant differences in both signs and symptoms of severe dry eye were seen at various time points throughout the study. Of particular note at day 56, the RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P=0.0141), and 59.1% reduction of total corneal fluorescein staining compared with vehicle control (P = 0.0108). Other improvements seen in the RGN-259-treated patients included tear film breakup time and increased tear volume production.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGRX:US $0.48 USD +0.0501

RGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RGRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,088.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,050.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERX BIOPHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at